Embecta to Acquire Owen Mumford for up to $199.4M

Embecta, a developer of diabetes care technology, began a deal to acquire Owen Mumford, a UK-based innovator and manufacturer of medical devices and drug delivery tech, in a transaction valued at up to £150 million ($199.4 million).

Under the agreement’s terms, embecta (formerly BD’s diabetes business) will acquire Owen Mumford for a cash payment of £100 million at closing and up to a further £50 million in performance-based payments.

Owen Mumford’s products include a quickly growing pharma services portfolio built on historic autoinjector success with established pharma companies, and an outlook supported by Aidaptus and other drug delivery devices. The company pioneered the first plastic autoinjector and now specializes in design and manufacture of drug delivery devices.

The company also has a portfolio of medical devices across point-of-care testing, self-injection, and pelvic health devices.

“We are extremely pleased to announce this agreement to acquire Owen Mumford, a company that has earned a global reputation for innovation, quality and patient‑centered design,” said Devdatt (Dev) Kurdikar, chairman, president, and CEO of embecta. “This acquisition is expected to sustainably improve embecta’s revenue growth trajectory and will accelerate our strategic transformation into a broad-based medical supplies company which provides drug delivery platforms to pharmaceutical companies and serves chronic care patients in the obesity, diabetes, autoimmune diseases and anaphylaxis markets.”

By combining Owen Mumford’s device design, molding and assembly capabilities in drug-delivery systems with embecta’s large-scale manufacturing expertise, creating opportunities for operational efficiencies and expanded capacity to support future product programs.

“Owen Mumford has a 70-year track-record of developing innovative solutions with long-term growth potential,” said Gavin Jones, managing director of Owen Mumford. “With our complementary portfolios and manufacturing expertise, and by leveraging embecta’s commercial scale, we will continue to drive innovation that improves the quality of life for people living with chronic conditions and other healthcare needs while creating new opportunities for our valued customers and the Owen Mumford team.”